Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study.

Journal Article (Journal Article)

BACKGROUND: Polycystic ovary syndrome (PCOS) is a complex endocrine disorder with an estimated prevalence of 4-21% in reproductive aged women. Recently, the Ovarian Cancer Association Consortium (OCAC) reported a decreased risk of invasive ovarian cancer among women with self-reported PCOS. However, given the limitations of self-reported PCOS, the validity of these observed associations remains uncertain. Therefore, we sought to use Mendelian randomization with genetic markers as a proxy for PCOS, to examine the association between PCOS and ovarian cancer. METHODS: Utilizing 14 single nucleotide polymorphisms (SNPs) previously associated with PCOS we assessed the association between genetically predicted PCOS and ovarian cancer risk, overall and by histotype, using summary statistics from a previously conducted genome-wide association study (GWAS) of ovarian cancer among European ancestry women within the OCAC (22 406 with invasive disease, 3103 with borderline disease and 40 941 controls). RESULTS: An inverse association was observed between genetically predicted PCOS and invasive ovarian cancer risk: odds ratio (OR)=0.92 [95% confidence interval (CI)=0.85-0.99; P = 0.03]. When results were examined by histotype, the strongest inverse association was observed between genetically predicted PCOS and endometrioid tumors (OR = 0.77; 95% CI = 0.65-0.92; P = 0.003). Adjustment for individual-level body mass index, oral contraceptive use and parity did not materially change the associations. CONCLUSION: Our study provides evidence for a relationship between PCOS and reduced ovarian cancer risk, overall and among specific histotypes of invasive ovarian cancer. These results lend support to our previous observational study results. Future studies are needed to understand mechanisms underlying this association.

Full Text

Duke Authors

Cited Authors

  • Harris, HR; Cushing-Haugen, KL; Webb, PM; Nagle, CM; Jordan, SJ; Australian Ovarian Cancer Study Group, ; Risch, HA; Rossing, MA; Doherty, JA; Goodman, MT; Modugno, F; Ness, RB; Moysich, KB; Kjær, SK; Høgdall, E; Jensen, A; Schildkraut, JM; Berchuck, A; Cramer, DW; Bandera, EV; Rodriguez, L; Wentzensen, N; Kotsopoulos, J; Narod, SA; McLaughlin, JR; Anton-Culver, H; Ziogas, A; Pearce, CL; Wu, AH; Lindström, S; Terry, KL

Published Date

  • June 1, 2019

Published In

Volume / Issue

  • 48 / 3

Start / End Page

  • 822 - 830

PubMed ID

  • 31211375

Pubmed Central ID

  • PMC6659359

Electronic International Standard Serial Number (EISSN)

  • 1464-3685

Digital Object Identifier (DOI)

  • 10.1093/ije/dyz113


  • eng

Conference Location

  • England